Norway · Delayed Price · Currency is NOK Medistim ASA Statistics
Total Valuation
Medistim ASA has a market cap or net worth of NOK 4.50 billion. The enterprise value is 4.43 billion.
| Market Cap | 4.50B |
| Enterprise Value | 4.43B |
Important Dates
The last earnings date was Friday, August 21, 2026.
| Earnings Date | Aug 21, 2026 |
| Ex-Dividend Date | May 7, 2026 |
Share Statistics
Medistim ASA has 18.29 million shares outstanding. The number of shares has decreased by -0.06% in one year.
| Current Share Class | 18.29M |
| Shares Outstanding | 18.29M |
| Shares Change (YoY) | -0.06% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 69.29% |
| Float | 13.13M |
Valuation Ratios
The trailing PE ratio is 27.21 and the forward PE ratio is 23.60.
| PE Ratio | 27.21 |
| Forward PE | 23.60 |
| PS Ratio | 5.98 |
| PB Ratio | 10.95 |
| P/TBV Ratio | 14.54 |
| P/FCF Ratio | 24.98 |
| P/OCF Ratio | 24.24 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.22, with an EV/FCF ratio of 24.62.
| EV / Earnings | 26.83 |
| EV / Sales | 5.89 |
| EV / EBITDA | 20.22 |
| EV / EBIT | 21.61 |
| EV / FCF | 24.62 |
Financial Position
The company has a current ratio of 3.15, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.15 |
| Quick Ratio | 1.88 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.19 |
| Interest Coverage | 377.30 |
Financial Efficiency
Return on equity (ROE) is 41.59% and return on invested capital (ROIC) is 46.77%.
| Return on Equity (ROE) | 41.59% |
| Return on Assets (ROA) | 22.97% |
| Return on Invested Capital (ROIC) | 46.77% |
| Return on Capital Employed (ROCE) | 44.72% |
| Weighted Average Cost of Capital (WACC) | 9.71% |
| Revenue Per Employee | 4.73M |
| Profits Per Employee | 1.04M |
| Employee Count | 159 |
| Asset Turnover | 1.35 |
| Inventory Turnover | 0.87 |
Taxes
In the past 12 months, Medistim ASA has paid 48.93 million in taxes.
| Income Tax | 48.93M |
| Effective Tax Rate | 22.84% |
Stock Price Statistics
The stock price has increased by +0.82% in the last 52 weeks. The beta is 1.01, so Medistim ASA's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | +0.82% |
| 50-Day Moving Average | 236.40 |
| 200-Day Moving Average | 231.74 |
| Relative Strength Index (RSI) | 51.81 |
| Average Volume (20 Days) | 16,375 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Medistim ASA had revenue of NOK 752.84 million and earned 165.30 million in profits. Earnings per share was 9.04.
| Revenue | 752.84M |
| Gross Profit | 608.69M |
| Operating Income | 205.25M |
| Pretax Income | 214.23M |
| Net Income | 165.30M |
| EBITDA | 210.46M |
| EBIT | 205.25M |
| Earnings Per Share (EPS) | 9.04 |
Balance Sheet
The company has 100.15 million in cash and 34.79 million in debt, with a net cash position of 65.36 million or 3.57 per share.
| Cash & Cash Equivalents | 100.15M |
| Total Debt | 34.79M |
| Net Cash | 65.36M |
| Net Cash Per Share | 3.57 |
| Equity (Book Value) | 411.01M |
| Book Value Per Share | 22.47 |
| Working Capital | 264.50M |
Cash Flow
In the last 12 months, operating cash flow was 185.65 million and capital expenditures -5.49 million, giving a free cash flow of 180.16 million.
| Operating Cash Flow | 185.65M |
| Capital Expenditures | -5.49M |
| Depreciation & Amortization | 5.21M |
| Net Borrowing | -11.06M |
| Free Cash Flow | 180.16M |
| FCF Per Share | 9.85 |
Margins
Gross margin is 80.85%, with operating and profit margins of 27.26% and 21.96%.
| Gross Margin | 80.85% |
| Operating Margin | 27.26% |
| Pretax Margin | 28.46% |
| Profit Margin | 21.96% |
| EBITDA Margin | 27.96% |
| EBIT Margin | 27.26% |
| FCF Margin | 23.93% |
Dividends & Yields
This stock pays an annual dividend of 8.00, which amounts to a dividend yield of 3.19%.
| Dividend Per Share | 8.00 |
| Dividend Yield | 3.19% |
| Dividend Growth (YoY) | 33.33% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 88.28% |
| Buyback Yield | 0.06% |
| Shareholder Yield | 3.25% |
| Earnings Yield | 3.67% |
| FCF Yield | 4.00% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Medistim ASA is 332.50, which is 35.16% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 332.50 |
| Price Target Difference | 35.16% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 10.44% |
| EPS Growth Forecast (3Y) | 10.49% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |